United States - English - NLM (National Library of Medicine)

hospira, inc. - zinc chloride (unii: 86q357l16b) (zinc cation - unii:13s1s8sf37) - zinc cation 1 mg in 1 ml - zinc 1 mg/ml (zinc chloride injection, usp) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. administration helps to maintain zinc serum levels and to prevent depletion of endogenous stores, and subsequent deficiency symptoms. none known. none known.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - testosterone, quantity: 24.3 mg - drug delivery system, transdermal - excipient ingredients: ethanol; sodium hydroxide; glyceryl monooleate; methyl laurate; carbomer copolymer (type b); glycerol; purified water; ethyl acetate; toluene; acrylates/va copolymer - indicated for testosterone replacement therapy for confirmed testosterone deficiency in males.

United States - English - NLM (National Library of Medicine)

endo pharmaceuticals inc. - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocaine 50 mg in 1 g - lidoderm is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate anhydrous (unii: 0j6z13x3wo) (zinc cation - unii:13s1s8sf37) - zinc cation 1 mg in 1 ml - zinc sulfate injection, usp is indicated for use as a supplement to intravenous solutions given for tpn. administration helps to maintain plasma levels and to prevent depletion of endogenous stores. zinc sulfate injection, usp should not be given undiluted by direct injection into a peripheral vein because of the likelihood of infusion phlebitis and the potential to increase renal loss of zinc from a bolus injection.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - testosterone 2 mg in 1 d - androderm is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism,  bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. these men usually have low serum testosterone concentrations and gonadotropins (fsh, lh) above the normal range. - hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. these men have low testosterone serum concentrations but have gonadotropins in the normal or low range. limitations of use - safety and efficacy of androderm in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. - safety and efficacy of andro

United States - English - NLM (National Library of Medicine)

tpu pharma, inc. - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidoderm is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - testosterone -

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - testosterone 1.41%{relative} (12.2mg/system);   - transdermal patch - 12.2 mg - active: testosterone 1.41%{relative} (12.2mg/system)   excipient: ethanol glycerol glyceryl mono-oleate carbomer copolymer (type b) methyl laurate purified water sodium hydroxide - androderm® is indicated for testosterone replacement therapy for confirmed testosterone deficiency in males.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - testosterone 24.3mg;   - transdermal patch - 24.3 mg - active: testosterone 24.3mg   excipient: ethanol glycerol glycerol mono-oleate carbomer copolymer type b methyl laurate purified water sodium hydroxide - androderm® is indicated for testosterone replacement therapy for confirmed testosterone deficiency in males.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - buprenorphine, quantity: 40 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - bupredermal patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. bupredermal patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. bupredermal patches are not indicated as an as-needed (prn) analgesia.